Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur MSD announces Gardasil’s additional protection

Sanofi Pasteur MSD announces Gardasil’s additional protection

21st September 2007

Sanofi Pasteur MSD has announced that its cervical cancer vaccine, Gardasil, has demonstrated prevention of pre-cancerous cervical lesions that are due to additional cancer-causing human papillomavirus types.

The company, a joint-venture between Sanofi Pasteur and Merck, Sharp and Dohme (MSD), presented the results at the 47th annual Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, as part of an analysis of two large phase III studies on Gardasil.

The cervical cancer vaccine was shown to provide cross-protection against pre-cancerous lesions caused by ten additional virus types as well as by virus types directly targeted by the vaccine.

“The prevention of pre-cancerous cervical lesions caused by additional virus types demonstrates that Gardasil can provide cross-protective efficacy and therefore could provide additional protection from cervical cancer caused by these virus types not directly targeted by the vaccine,” said Patrick Poirot, vice-president for medical and scientific affairs at Sanofi Pasteur MSD.

He added that cross-protective efficacy was lower than direct efficacy because of the differences in additional virus types and insisted that Gardasil’s true weight came with direct protection.

Earlier this year MSD announced that the Food and Drug Administration (FDA) in the US had accepted a supplemental Biologics License Application (sBLA) for the Gardasil.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.